Somnomed Limited · ASX:SOM
Somnomed — Investor Presentation (April 2024)
16 slides from Somnomed's investor presentation, Apr 9, 2024
Slide 1: Investor Presentation
For personal use only Investor Presentation April 2024
Slide 2: SomnoMed’s opportunity
SomnoMed’s opportunity VISION INVESTMENT HIGHLIGHTS For personal use only Our vision is to lead in the treatment of Significant total addressable market with 900+ million individuals patients suffering from obstructive sleep suffering from OSA globally apnea and relevant adjacent conditions SomnoMed
Slide 3: Contents
Contents Section Title Slide For personal use only 1 Business Update 4 2 Strategic Plan and Use of Funds 7 3 Capital Raising Details 10 4 Important Notices and Disclaimer 14 © April 2024 SomnoMed 3
Slide 4: Business update
For personal use only Business update
Slide 5: Operational challenges have emerged that are impacting financial performance
Operational challenges have emerged that are impacting financial performance Manufacturing capacity issues and constraints Cost efficiency delays Financial impacts For personal use only • In the Quarterly Update for Q2 FY24 released in January 2024 the Company advised of manufacturing • Planned cost
Slide 6: FY24 revised guidance
FY24 revised guidance1 Revenue Growth EBITDA2 Capex 6% – 9% $(1) – $0m $5m For personal use only vs previous guidance of 12%+ vs previous guidance of $3m+ unchanged vs previous guidance • For the 9 months to 31 March 2024, • Estimated $(3) million impact at the • Includes approximately $3 million of
Slide 7: Strategic plan and use of funds
Strategic plan and use of funds For personal use only
Slide 8: SomnoMed’s market opportunity and long-term strategy remain unchanged
SomnoMed’s market opportunity and long-term strategy remain unchanged Four main levers to build on SomnoMed’s leadership position in the large obstructive sleep apnea (OSA) market Achieve financial flexibility and Invest in manufacturing capacity Continue leadership in device Drive cost efficiency F
Slide 9: Use of funds and long-term aspirations
Use of funds and long-term aspirations Investing to set the business up to deliver on key FY27 aspirations Use of funds over the next 12 – 18 months1 FY27 aspirations $m For personal use only Clean balance sheet and reduce costs (annual 14.5 savings >$6.7m)2 Pay out Epsilon Direct Lending Facility 1
Slide 10: Capital raising details
Capital raising details For personal use only
Slide 11: Capital raising details
Capital raising details • $22.6 million capital raising comprising a 1 for 1.01 pro rata accelerated non-renounceable entitlement offer (“Entitlement Offer”) • The Entitlement Offer comprises: Offer size and • An institutional offer to raise approximately $6.6 million (“Institutional Entitlement Off
Slide 12: Capital raising details (continued)
Capital raising details (continued) • The Company’s largest shareholder, TDM Growth Partners Pty Ltd (“TDM”), has confirmed that it will take up its full Entitlement under the retail tranche of the Entitlement Offer and has also agreed to sub-underwrite the Entitlement Offer should there be any shor
Slide 13: Timetable
Timetable Event Date (2024) Prospectus lodged, Institutional Entitlement Offer opens Tuesday, 9 April Institutional Entitlement Offer closes Tuesday, 9 April For personal use only Suspension lifted, trading resumes on an ex-entitlement basis Wednesday, 10 April Record date for the Entitlement Offer
Slide 14: Important notices and disclaimer
Important notices and For personal use only disclaimer
Slide 15: Important notices and disclaimer
Important notices and disclaimer The following notice and disclaimer applies to this investor presentation (Presentation) and you are therefore advised to read this carefully before reading or making any other use of this Presentation or any information contained in this Presentation. By accepting,
Slide 16: Important notices and disclaimer
Important notices and disclaimer Financial data All dollar values are in Australian dollars (A$ or AUD) unless stated otherwise. This Presentation (and the Prospectus) includes certain financial information as at 31 December 2023 and revised FY24 guidance (Financial Information). The Financial Infor